ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1
1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Spain) Eurican SHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Austria and Germany) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of lyophilisate contains: Active substances: Minimum Maximum Canine Distemper virus, strain BA5 10 4.0 CCID 50 * 10 6.0 CCID 50 * Canine Adenovirus type 2, strain DK13 10 2.5 CCID 50 * 10 6.3 CCID 50 * Canine Parvovirus type 2, strain CAG2 10 4.9 CCID 50 * 10 7.1 CCID 50 * Canine Parainfluenza virus type 2, strain 10 4.7 CCID 50 * 10 7.1 CCID 50 * CGF 2004/75 (* CCID 50 : 50% cell culture infective dose) One dose (1ml) of suspension contains: Active substances: Inactivated Leptospira interrogans serogroup and serovar Canicola strain 16070... Activity acc. to Ph. Eur.447* Inactivated Leptospira interrogans serogroup and serovar Icterohaemorrhagiae strain16069... Activity acc. to Ph. Eur.447* Inactivated Leptospira interrogans serogroup and serovar Grippotyphosa strain Grippo Mal 1540...Activity acc. to Ph. Eur.447* * 80% protection in hamsters Excipients: For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate and suspension for suspension for injection. Beige to pale yellow lyophilisate and opalescent, homogenous suspension 4. CLINICAL PARTICULARS 4.1 Target species Dogs 2
4.2 Indications for use, specifying the target species Active immunisation of dogs to: - prevent mortality and clinical signs caused by Distemper virus - prevent mortality and clinical signs caused by infectious canine hepatitis virus, - reduce viral excretion during respiratory disease caused by canine adenovirus type 2, - prevent mortality, clinical signs and viral excretion caused by canine parvovirus, - reduce viral excretion caused by canine parainfluenza virus type 2, - prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae - prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. - prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. Onset of immunity: 2 weeks for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains. Protection has been demonstrated against canine parvovirus type 2a, 2b and 2c for at least one year either by challenge (type 2b) or serology (type 2a and 2c). * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. 4.3 Contraindications None 4.4 Special warnings for each target species None. 4.5 Special precautions for use Special precautions for use in animals Vaccinate only healthy animals. Apply usual aseptic procedures. After vaccination, the live CAV-2 and CPV vaccine strains can transiently be shed without adverse consequence for in-contact animals. Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 Adverse reactions (frequency and seriousness) Immediately after injection, a slight swelling ( 2 cm) at the injection site may commonly be observed, usually regressing within 1-6 days. This can, on some occasions, be accompanied by slight pruritus, heat and pain at the injection site. Transient lethargy and emesis may also be observed. Uncommon reactions such as anorexia, polydipsia, hyperthermia, diarrhoea, muscle tremor, muscle weakness and injection site cutaneous lesions may be observed. 3
As with any vaccine, rare hypersensitivity reactions may occur. In such cases, appropriate symptomatic treatment should be provided. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 4.7 Use during pregnancy, lactation or lay Can be used during pregnancy 4.8 Interaction with other medicinal products and other forms of interaction Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Merial's rabies vaccine in dogs from 12 weeks of age. In that case, the efficacy against Leptospira Icterohaemorrhagiae was demonstrated only for the reduction of renal lesions and bacterial excretion, and the efficacy against Leptospira Grippotyphosa was demonstrated only for the reduction of renal carriage, renal lesions and bacterial excretion. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. 4.9 Amounts to be administered and administration route Aseptically reconstitute the contents of the lyophilisate with the suspension for injection. Shake well before use. The entire contents of the reconstituted vial should be administered as a single dose. The reconstituted content shall be an opalescent yellow to orange suspension. Inject a 1-ml dose subcutaneously according to the following schedule: Primary vaccination: Two injections separated by an interval of 4 weeks from 7 weeks of age. In cases where high levels of maternally derived antibodies are suspected by the veterinarian and the primary vaccination course was completed before 16 weeks of age, a third injection using a Merial vaccine containing Distemper, Adenovirus and Parvovirus is recommended from 16 weeks of age, at least 3 weeks after the second injection. Revaccination: Administer one dose 12 months after completion of the primary vaccination course. Dogs should be revaccinated with a single booster dose on an annual basis. 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary No adverse reactions other than those mentioned in section 4.6 were observed after administration of a 10-fold overdose of the lyophilisate and 2-fold overdose of the suspension. 4
4.11 Withdrawal period(s) Not applicable. 5. IMMUNOLOGICAL PROPERTIES Pharmacotherapeutic group: Live viral and inactivated bacterial vaccines ATC vet code: QI07AI02 Vaccine against distemper, adenoviroses (CAV-1 and CAV-2), parvovirosis and parainfluenza type 2 respiratory infections (attenuated) and Leptospira (inactivated) in dogs. After administration, the vaccine induces an immune response against distemper, adenoviroses (CAV-1 and CAV-2), parvovirosis, parainfluenza type 2 respiratory infections and Leptospira interrogans serogroup Canicola, Leptospira interrogans serogroup Icterohaemorrhagiae and Leptospira kirschneri serogroup Grippotyphosa leptospirosis in the dog demonstrated by challenge and by the presence of antibodies. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Lyophilisate Casein hydrolysate Gelatin Dextran 40 Dipotassium phosphate Potassium dihydrogen phosphate Potassium hydroxide Sorbitol Sucrose Water for injection Suspension Potassium chloride Sodium chloride Potassium dihydrogen phosphate Disodium phosphate dihydrate Water for injections 6.2 Incompatibilities Do not mix with any other veterinary medicinal product except the suspension supplied for use with the product. 6.3 Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 2 years Shelf life after reconstitution according to directions: use immediately 6.4. Special precautions for storage Store and transport refrigerated (2 C-8 C) Do not freeze. Protect from light. 5
6.5 Nature and composition of immediate packaging Type I glass vials with chlorobutyl stoppers, sealed with aluminium caps. Plastic box of 10 vials (glass) of lyophilisate (1 dose) and 10 vials (glass) of suspension (1 ml). Plastic box of 25 vials (glass) of lyophilisate (1 dose) and 25 vials (glass) of suspension (1 ml). Plastic box of 50 vials (glass) of lyophilisate (1 dose) and 50 vials (glass) of suspension (1 ml). Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER MERIAL 29 Avenue Tony Garnier 69007 Lyon France 8. MARKETING AUTHORISATION NUMBER(S) 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 10 DATE OF REVISION OF THE TEXT PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable 6
ANNEX III LABELLING AND PACKAGE LEAFLET 7
A. LABELLING 8
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Box of 10 doses: 10 vials (glass) of 1 dose of lyophilisate and 10 vials (glass) of 1 ml of solvent for suspension. Box of 25 doses: 25 vials (glass) of 1 dose of lyophilisate and 25 vials (glass) of 1 ml of solvent for suspension. Box of 50 doses: 50 vials (glass) of 1 dose of lyophilisate and 50 vials (glass) of 1 ml of solvent for suspension. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Spain) Eurican SHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Austria and Germany) 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Attenuated distemper virus... 10 4.0-6.0 CCID 50 Attenuated canine adenovirus type 2... 10 2.5-6.3 CCID 50 Attenuated canine parvovirus... 10 4.9-7.1 CCID 50 Attenuated canine parainfluenza type 2 virus... 10 4.7-7.1 CCID 50 Inactivated Leptospira strains*... activity acc. Ph.Eur.447** *Leptospira serogroup and serovar Canicola, Icterohaemorrhagiae, Grippotyphosa ** 80% of protection in hamsters 3. PHARMACEUTICAL FORM Lyophilisate and suspension for suspension for injection. 4. PACKAGE SIZE 10 doses : 10x1 dose lyophilisate + 10x1ml suspension. 25 doses : 25x1 dose lyophilisate + 25x1ml suspension. 50 doses : 50x1 dose lyophilisate + 50x1ml suspension. 5. TARGET SPECIES Dogs 6. INDICATION(S) 7. METHOD AND ROUTE(S) OF ADMINISTRATION 9
Subcutaneous use Read the package leaflet before use. 8. WITHDRAWAL PERIOD Not applicable 9. SPECIAL WARNING(S), IF NECESSARY Read the package leaflet before use. 10. EXPIRY DATE EXP {month/year} Use immediately after reconstitution. 11. SPECIAL STORAGE CONDITIONS Store and transport refrigerated (2 C-8 C) Do not freeze Protect from light 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY Disposal: Read the package leaflet before use. 13. THE WORDS FOR ANIMAL TREATMENT ONLY AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE For animal treatment only - To be supplied only on veterinary prescription. 14. THE WORDS KEEP OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER MERIAL 29 Avenue Tony Garnier 69007 Lyon France 16. MARKETING AUTHORISATION NUMBER(S) 10
17. MANUFACTURER S BATCH NUMBER Lot 11
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Lyophilisate:1 dose 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi (for Spain) Eurican SHPPi 2 -L multi (for Austria and Germany) 2. QUANTITY OF THE ACTIVE SUBSTANCE(S) DHPPi 2 (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) CHPPi 2 (for Belgium, Estonia, France, Luxemburg and Portugal) MHPPi 2 (for Spain) SHPPi 2 (for Austria and Germany) Read package leaflet before use. 3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 1 dose 4. ROUTE(S) OF ADMINISTRATION SC 5. WITHDRAWAL PERIOD Not applicable 6. BATCH NUMBER Lot 7. EXPIRY DATE EXP {month/year} 8. THE WORDS FOR ANIMAL TREATMENT ONLY 12
For animal treatment only 13
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Suspension:1 ml 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi (for Spain) Eurican SHPPi 2 -L multi (for Austria and Germany) 2. QUANTITY OF THE ACTIVE SUBSTANCE(S) L multi Read package leaflet before use. 3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 1 ml 4. ROUTE(S) OF ADMINISTRATION SC 5. WITHDRAWAL PERIOD Not applicable 6. BATCH NUMBER Lot: 7. EXPIRY DATE EXP {month/year} 8. THE WORDS FOR ANIMAL TREATMENT ONLY For animal treatment only 14
B. PACKAGE LEAFLET 15
PACKAGE LEAFLET FOR: Eurican DHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Spain) Eurican SHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Austria and Germany) 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder : MERIAL 29 Avenue Tony Garnier 69007 Lyon France Manufacturer responsible for batch release: MERIAL, Laboratoire Porte des Alpes Rue de l'aviation 69800 Saint-Priest France 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Spain) Eurican SHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Austria and Germany) 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) One dose of lyophilisate contains: Minimum Maximum Canine Distemper virus, strain BA5 10 4.0 CCID 50 * 10 6.0 CCID 50 * Canine Adenovirus type 2, strain DK13 10 2.5 CCID 50 * 10 6.3 CCID 50 * Canine Parvovirus type 2, strain CAG2 10 4.9 CCID 50 * 10 7.1 CCID 50 * Canine Parainfluenza virus type 2, strain 10 4.7 CCID 50 * 10 7.1 CCID 50 * CGF 2004/75 (* CCID 50 : 50% cell culture infective dose) One dose (1ml) of suspension contains: Inactivated Leptospira interrogans serogroup and serovar Canicola strain 16070... Activity acc. to Ph. Eur.447* Inactivated Leptospira interrogans serogroup and serovar Icterohaemorrhagiae strain16069... Activity acc. to Ph. Eur.447* 16
Inactivated Leptospira interrogans serogroup and serovar Grippotyphosa strain Grippo Mal 1540...Activity acc. to Ph. Eur.447* * 80% protection in hamsters Beige to pale yellow lyophilisate and opalescent, homogenous suspension 4. INDICATIONS Active immunisation of dogs to: - prevent mortality and clinical signs caused by Distemper virus - prevent mortality and clinical signs caused by infectious canine hepatitis virus, - reduce viral excretion during respiratory disease caused by canine adenovirus type 2, - prevent mortality, clinical signs and viral excretion caused by canine parvovirus, - reduce viral excretion caused by canine parainfluenza virus type 2, - prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae - prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. - prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. Onset of immunity: 2 weeks for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains. Protection has been demonstrated against canine parvovirus type 2a, 2b and 2c for at least one year either by challenge (type 2b) or serology (type 2a and 2c). * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. 5. CONTRAINDICATIONS None 6. ADVERSE REACTIONS Immediately after injection, a slight swelling ( 2 cm) at the injection site may commonly be observed, usually regressing within 1-6 days. This can, on some occasions, be accompanied by slight pruritus, heat and pain at the injection site. Transient lethargy and emesis may also be observed. Uncommon reactions such as anorexia, polydipsia, hyperthermia, diarrhoea, muscle tremor, muscle weakness and injection site cutaneous lesions may be observed. As with any vaccine, rare, occasional hypersensitivity reactions may occur. In such cases, appropriate symptomatic treatment should be provided. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 17
If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon. 7. TARGET SPECIES Dogs 8. DOSAGE FOR EACH SPECIES, ROUTEAND METHOD OF ADMINISTRATION After reconstitution, inject a 1-ml dose subcutaneously according to the following schedule: Primary vaccination: Two injections separated by an interval of 4 weeks from 7 weeks of age. In cases where high levels of maternally derived antibodies are suspected by the veterinarian and the primary vaccination course was completed before 16 weeks of age, a third injection using a Merial vaccine containing Distemper, Adenovirus and Parvovirus is recommended from 16 weeks of age, at least 3 weeks after the second injection. Revaccination: Administer one dose 12 months after completion of the primary vaccination course. Dogs should be revaccinated with a single booster dose on an annual basis. 9. ADVICE ON CORRECT ADMINISTRATION Aseptically reconstitute the contents of the lyophilisate with the suspension for injection. Shake well before use. The entire contents of the reconstituted vial should be administered as a single dose. The reconstituted content shall be an opalescent yellow to orange suspension. 10. WITHDRAWAL PERIOD Not applicable 11. SPECIAL STORAGE PRECAUTIONS Keep out of the sight and reach of children. Store and transport refrigerated (2 C-8 C). Do not freeze Protect from light. Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. Shelf-life after reconstitution according to directions: use immediately. 12. SPECIAL WARNINGS Special precautions for use in animals: Vaccinate only healthy animals. Apply usual aseptic procedures. After vaccination, the live CAV-2 and CPV vaccine strains can transiently be shed without adverse consequence for in-contact animals. Special precautions to be taken by the person administering the veterinary medicinal product to animals: 18
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Pregnancy: Can be used during pregnancy Interaction with other medicinal products and other forms of interaction: Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Merial s rabies vaccine in dogs from 12 weeks of age. In that case, the efficacy against Leptospira Icterohaemorrhagiae was demonstrated only for the reduction of renal lesions and bacterial excretion, and the efficacy against Leptospira Gripotyphosa was demonstrated only for the reduction of renal carriage, renal lesions and bacterial excretion. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis Overdose: No adverse reactions other than those mentioned in section adverse reactions were observed after administration of a 10-fold overdose of the lyophilisate and 2-fold overdose of the suspension. Incompatibilities: Do not mix with any other veterinary medicinal product except the suspension supplied for use with the product. 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED 15. OTHER INFORMATION Plastic box of 10 vials (glass) of lyophilisate (1 dose) and 10 vials (glass) of suspension(1 ml). Plastic box of 25 vials (glass) of lyophilisate (1 dose) and 25 vials (glass) of suspension (1 ml). Plastic box of 50 vials (glass) of lyophilisate (1 dose) and 50 vials (glass) of suspension (1 ml). Not all pack sizes may be marketed. 19